Pfizer’s low earnings multiple highlights the market’s split view of pharma earnings durability, while Johnson & Johnson trades at a premium

Shares of Pfizer and Johnson & Johnson are often discussed in the same breath because both are large, diversified drug and healthcare companies. But a recent Yahoo Finance market note said the market is valuing them very differently, with Pfizer trading at a forward P/E multiple under 10x while Johnson & Johnson commands more than twice that level.

Forward P/E is a valuation measure that compares a company’s current stock price to its forecast earnings over the next year or so. In the Yahoo Finance write-up, the key message was that Pfizer can look “cheap” on this metric, yet the apparent bargain is linked to expectations for earnings that are viewed as less favorable than those embedded in Johnson & Johnson’s higher multiple.

The same analysis suggested that Johnson & Johnson’s premium reflects a more solid view of earnings power. In contrast, Pfizer’s discount is presented as consistent with investors pricing in a weaker or more uncertain earnings trajectory, meaning the market is paying less for each dollar of expected profit.

The note also framed the comparison against peers by highlighting that Pfizer’s low earnings multiple is not explained solely by a broad, sector-wide de-rating of pharma. Instead, the article’s logic is that company-specific outlooks matter, especially for businesses whose future revenue and profit profiles depend on product pipelines, patent timelines, and competitive dynamics.

While the article’s thrust is comparative valuation, it also implicitly underscores how difficult it is to separate “low multiple” from “low expectations.” A company can trade at a lower forward P/E either because the forecast earnings are expected to be strong and the stock is inexpensive, or because the forecast earnings are expected to be weak, volatile, or at higher risk. The Yahoo Finance piece leaned toward the latter interpretation for Pfizer.

For Johnson & Johnson, the premium multiple described in the note indicates investors are willing to pay more relative to forecast earnings, generally indicating greater confidence in business stability. In large-cap healthcare, that confidence often rests on a mix of product diversification, distribution and consumer offtake, and the breadth of cash-generating segments, though the Yahoo Finance article did not provide segment-level or guidance-level details in the information available here.

A caveat is important: this story is based on the Yahoo Finance analysis framing around forward P/E levels and relative valuation. Without additional disclosure text, the specific assumptions behind each company’s forward earnings estimates, the forecast horizon used for the multiple, and any explicit management guidance were not available in the material provided for this review.

Looking ahead, investors typically watch whether forward earnings expectations converge or diverge further. If Pfizer’s forecast earnings outlook improves, its low multiple could compress, narrowing the gap versus Johnson & Johnson. Conversely, if uncertainty persists, the premium Johnson & Johnson receives on forward earnings metrics could remain a central feature of the valuation debate.